Serum brain-derived neurotrophic factor is related to platelet reactivity but not to genetic polymorphisms within BDNF encoding gene in patients with type 2 diabetes

Ceren Eyileten, Małgorzata Zaremba, Piotr Janicki, Marek Rosiak, Agnieszka Cudna, Agnieszka Kapłon-Cieślicka, Grzegorz Opolski, Krzysztof J. Filipiak, Dariusz A. Kosior, Dagmara Mirowska-Guzel, Marek Postula

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: The aim of this study was to investigate the association between serum concentrations of the brain-derived neurotrophic factor (BDNF), platelet reactivity and inflammatory markers, as well as its association with BDNF encoding gene variants in type 2 diabetic patients (T2DM) during acetylsalicylic acid (ASA) therapy. MATERIAL AND METHODS: This retrospective, open-label study enrolled 91 patients. Serum BDNF, genotype variants, hematological, biochemical, and inflammatory markers were measured. Blood samples were taken in the morning 2–3 h after the last ASA dose. The BDNF genotypes for selected variants were analyzed by use of the iPLEX Sequenom assay. RESULTS: In multivariate linear regression analysis, CADP-CT >74 sec (p<0.001) and sP-selectin concentration (p=0.03) were predictive of high serum BDNF. In multivariate logistic regression analysis, CADP-CT >74 sec (p=0.02) and IL-6 concentration (p=0.03) were risk factors for serum BDNF above the median. Non-significant differences were observed between intronic SNP rs925946, missense SNP rs6265, and intronic SNP rs4923463 allelic groups and BDNF concentrations in the investigated cohort. CONCLUSIONS: Chronic inflammatory condition and enhanced immune system are associated with the production of BDNF, which may be why the serum BDNF level in T2DM patients with high platelet reactivity was higher compared to subjects with normal platelet reactivity in this study.

Original languageEnglish (US)
Pages (from-to)69-76
Number of pages8
JournalMedical Science Monitor
Volume22
DOIs
StatePublished - Jan 7 2016

Fingerprint

Brain-Derived Neurotrophic Factor
Genetic Polymorphisms
Type 2 Diabetes Mellitus
Blood Platelets
Serum
Genes
Single Nucleotide Polymorphism
Aspirin
Genotype
Immune System
Linear Models
Interleukin-6
Biomarkers
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Eyileten, Ceren ; Zaremba, Małgorzata ; Janicki, Piotr ; Rosiak, Marek ; Cudna, Agnieszka ; Kapłon-Cieślicka, Agnieszka ; Opolski, Grzegorz ; Filipiak, Krzysztof J. ; Kosior, Dariusz A. ; Mirowska-Guzel, Dagmara ; Postula, Marek. / Serum brain-derived neurotrophic factor is related to platelet reactivity but not to genetic polymorphisms within BDNF encoding gene in patients with type 2 diabetes. In: Medical Science Monitor. 2016 ; Vol. 22. pp. 69-76.
@article{819b9adadf3e4db8b6cc1b9146b092a3,
title = "Serum brain-derived neurotrophic factor is related to platelet reactivity but not to genetic polymorphisms within BDNF encoding gene in patients with type 2 diabetes",
abstract = "BACKGROUND: The aim of this study was to investigate the association between serum concentrations of the brain-derived neurotrophic factor (BDNF), platelet reactivity and inflammatory markers, as well as its association with BDNF encoding gene variants in type 2 diabetic patients (T2DM) during acetylsalicylic acid (ASA) therapy. MATERIAL AND METHODS: This retrospective, open-label study enrolled 91 patients. Serum BDNF, genotype variants, hematological, biochemical, and inflammatory markers were measured. Blood samples were taken in the morning 2–3 h after the last ASA dose. The BDNF genotypes for selected variants were analyzed by use of the iPLEX Sequenom assay. RESULTS: In multivariate linear regression analysis, CADP-CT >74 sec (p<0.001) and sP-selectin concentration (p=0.03) were predictive of high serum BDNF. In multivariate logistic regression analysis, CADP-CT >74 sec (p=0.02) and IL-6 concentration (p=0.03) were risk factors for serum BDNF above the median. Non-significant differences were observed between intronic SNP rs925946, missense SNP rs6265, and intronic SNP rs4923463 allelic groups and BDNF concentrations in the investigated cohort. CONCLUSIONS: Chronic inflammatory condition and enhanced immune system are associated with the production of BDNF, which may be why the serum BDNF level in T2DM patients with high platelet reactivity was higher compared to subjects with normal platelet reactivity in this study.",
author = "Ceren Eyileten and Małgorzata Zaremba and Piotr Janicki and Marek Rosiak and Agnieszka Cudna and Agnieszka Kapłon-Cieślicka and Grzegorz Opolski and Filipiak, {Krzysztof J.} and Kosior, {Dariusz A.} and Dagmara Mirowska-Guzel and Marek Postula",
year = "2016",
month = "1",
day = "7",
doi = "10.12659/MSM.895607",
language = "English (US)",
volume = "22",
pages = "69--76",
journal = "Medical Science Monitor",
issn = "1234-1010",
publisher = "International Scientific Literature Inc.",

}

Eyileten, C, Zaremba, M, Janicki, P, Rosiak, M, Cudna, A, Kapłon-Cieślicka, A, Opolski, G, Filipiak, KJ, Kosior, DA, Mirowska-Guzel, D & Postula, M 2016, 'Serum brain-derived neurotrophic factor is related to platelet reactivity but not to genetic polymorphisms within BDNF encoding gene in patients with type 2 diabetes', Medical Science Monitor, vol. 22, pp. 69-76. https://doi.org/10.12659/MSM.895607

Serum brain-derived neurotrophic factor is related to platelet reactivity but not to genetic polymorphisms within BDNF encoding gene in patients with type 2 diabetes. / Eyileten, Ceren; Zaremba, Małgorzata; Janicki, Piotr; Rosiak, Marek; Cudna, Agnieszka; Kapłon-Cieślicka, Agnieszka; Opolski, Grzegorz; Filipiak, Krzysztof J.; Kosior, Dariusz A.; Mirowska-Guzel, Dagmara; Postula, Marek.

In: Medical Science Monitor, Vol. 22, 07.01.2016, p. 69-76.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum brain-derived neurotrophic factor is related to platelet reactivity but not to genetic polymorphisms within BDNF encoding gene in patients with type 2 diabetes

AU - Eyileten, Ceren

AU - Zaremba, Małgorzata

AU - Janicki, Piotr

AU - Rosiak, Marek

AU - Cudna, Agnieszka

AU - Kapłon-Cieślicka, Agnieszka

AU - Opolski, Grzegorz

AU - Filipiak, Krzysztof J.

AU - Kosior, Dariusz A.

AU - Mirowska-Guzel, Dagmara

AU - Postula, Marek

PY - 2016/1/7

Y1 - 2016/1/7

N2 - BACKGROUND: The aim of this study was to investigate the association between serum concentrations of the brain-derived neurotrophic factor (BDNF), platelet reactivity and inflammatory markers, as well as its association with BDNF encoding gene variants in type 2 diabetic patients (T2DM) during acetylsalicylic acid (ASA) therapy. MATERIAL AND METHODS: This retrospective, open-label study enrolled 91 patients. Serum BDNF, genotype variants, hematological, biochemical, and inflammatory markers were measured. Blood samples were taken in the morning 2–3 h after the last ASA dose. The BDNF genotypes for selected variants were analyzed by use of the iPLEX Sequenom assay. RESULTS: In multivariate linear regression analysis, CADP-CT >74 sec (p<0.001) and sP-selectin concentration (p=0.03) were predictive of high serum BDNF. In multivariate logistic regression analysis, CADP-CT >74 sec (p=0.02) and IL-6 concentration (p=0.03) were risk factors for serum BDNF above the median. Non-significant differences were observed between intronic SNP rs925946, missense SNP rs6265, and intronic SNP rs4923463 allelic groups and BDNF concentrations in the investigated cohort. CONCLUSIONS: Chronic inflammatory condition and enhanced immune system are associated with the production of BDNF, which may be why the serum BDNF level in T2DM patients with high platelet reactivity was higher compared to subjects with normal platelet reactivity in this study.

AB - BACKGROUND: The aim of this study was to investigate the association between serum concentrations of the brain-derived neurotrophic factor (BDNF), platelet reactivity and inflammatory markers, as well as its association with BDNF encoding gene variants in type 2 diabetic patients (T2DM) during acetylsalicylic acid (ASA) therapy. MATERIAL AND METHODS: This retrospective, open-label study enrolled 91 patients. Serum BDNF, genotype variants, hematological, biochemical, and inflammatory markers were measured. Blood samples were taken in the morning 2–3 h after the last ASA dose. The BDNF genotypes for selected variants were analyzed by use of the iPLEX Sequenom assay. RESULTS: In multivariate linear regression analysis, CADP-CT >74 sec (p<0.001) and sP-selectin concentration (p=0.03) were predictive of high serum BDNF. In multivariate logistic regression analysis, CADP-CT >74 sec (p=0.02) and IL-6 concentration (p=0.03) were risk factors for serum BDNF above the median. Non-significant differences were observed between intronic SNP rs925946, missense SNP rs6265, and intronic SNP rs4923463 allelic groups and BDNF concentrations in the investigated cohort. CONCLUSIONS: Chronic inflammatory condition and enhanced immune system are associated with the production of BDNF, which may be why the serum BDNF level in T2DM patients with high platelet reactivity was higher compared to subjects with normal platelet reactivity in this study.

UR - http://www.scopus.com/inward/record.url?scp=84954349917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954349917&partnerID=8YFLogxK

U2 - 10.12659/MSM.895607

DO - 10.12659/MSM.895607

M3 - Article

VL - 22

SP - 69

EP - 76

JO - Medical Science Monitor

JF - Medical Science Monitor

SN - 1234-1010

ER -